A statistical framework based on the meta-analysis of expression profiles to identify pan-cancer markers and mechanisms of drug response using large panels of cancer cell lines from numerous distinct lineages characterized that the constitutive activation of several signaling pathways, including the interferon/Stat1 pathway, is implicated in resistance to the pan-histone deacetylase (HDAC) inhibitor [42]. The gene discussed is STAT1; the disease is cancer.